相关临床试验
94
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
18
19.1%
已完成
51
54.3%
招募中
14
14.9%
终止
2
2.1%
Unknown
7
7.5%
撤回
2
2.1%
暂无批准数据
- Promomed will invest 1.4 billion roubles to launch small-batch production of high-tech drugs and active pharmaceutical ingredients for rare diseases, including Duchenne muscular dystrophy and short bowel syndrome. - The project receives 940 million roubles in subsidized financing from Russia's Industrial Development Fund, with production capacity expected to reach 47,000 packs per year by 2031. - Promomed's founder Pyotr Bely says small-batch production capacity is virtually non-existent in Russia, leaving patients dependent on expensive foreign manufacturers with unstable supply. - The initiative reflects a broader shift among Russian drugmakers toward orphan drugs, driven by unmet needs, government incentives, and guaranteed sales through the state-run Circle of Kindness foundation.
- Biocad has opened patient enrollment for a Phase III trial comparing its trastuzumab emtansine biosimilar BCD-237 against Roche's original Kadcyla in HER2-positive breast cancer. - The study will enroll 488 female patients across 48 clinical centers in Russia, with completion expected by the end of 2031. - Kadcyla remains the only trastuzumab emtansine product registered in Russia and ranked among the top five hospital procurement drugs by value in 2025. - The original Kadcyla was approved in the U.S. in 2013 as the first ADC for HER2-positive breast cancer and was registered in Russia in 2014.
